Pursuant to the provisions of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of advertisement published on January 22, 2026, in Business Standard (English) and Business Standard (Hindi) newspaper providing Extracts of Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025.We request you to take the above on record.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals has submitted copies of newspaper advertisements published on January 22, 2026, in Business Standard (English and Hindi editions). The advertisements contain extracts of the company's unaudited financial results for the quarter and nine months ended December 31, 2025. This filing is made under Regulation 47 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015, and is a routine compliance requirement. The actual financial results themselves are not detailed in this filing — only the fact that their extracts were published in newspapers is being disclosed to the exchange.
This is a routine regulatory compliance filing with no new financial information. Shareholders seeking the detailed Q3 FY26 results should refer to the company's earlier financial results filing or the published newspaper extracts. No material impact on stock price is expected from this disclosure alone.